Author Correction: Autologous T cell therapy for PRAME⁺ advanced solid tumors in HLA-A*02⁺ patients: a phase 1 trial

Affiliations

¹ Department of Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany.
² National Center for Tumor Diseases, Dresden, Germany.
³ Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.
⁵ Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, University Hospital Bonn, Bonn, Germany.
⁷ Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Columbia University Medical Center, New York, NY, USA.
⁹ Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹⁰ Department of Oncology, Hematology, and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹¹ Immatics Biotechnologies GmbH, Tübingen, Germany.
¹² Immatics US, Inc., Houston, TX, USA.
¹³ Institute of Immunology, Eberhard Karls University Tübingen, Tübingen, Germany.
¹⁴ Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
¹⁵ Immatics Biotechnologies GmbH, Tübingen, Germany. cedrik.britten@immatics.com.

^# Contributed equally.

Published Erratum

Martin Wermke et al. Nat Med. 2025 Jul.

. 2025 Jul;31(7):2453.

doi: 10.1038/s41591-025-03731-6.

¹ Department of Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany.
² National Center for Tumor Diseases, Dresden, Germany.
³ Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.
⁵ Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, University Hospital Bonn, Bonn, Germany.
⁷ Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Columbia University Medical Center, New York, NY, USA.
⁹ Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹⁰ Department of Oncology, Hematology, and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹¹ Immatics Biotechnologies GmbH, Tübingen, Germany.
¹² Immatics US, Inc., Houston, TX, USA.
¹³ Institute of Immunology, Eberhard Karls University Tübingen, Tübingen, Germany.
¹⁴ Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
¹⁵ Immatics Biotechnologies GmbH, Tübingen, Germany. cedrik.britten@immatics.com.

^# Contributed equally.

No abstract available

Erratum for

Autologous T cell therapy for PRAME⁺ advanced solid tumors in HLA-A*02⁺ patients: a phase 1 trial.
Wermke M, Araujo DM, Chatterjee M, Tsimberidou AM, Holderried TAW, Jazaeri AA, Reshef R, Bokemeyer C, Alsdorf W, Wetzko K, Brossart P, Aslan K, Backert L, Bunk S, Fritsche J, Gulde S, Hengler S, Hilf N, Hossain MB, Hukelmann J, Kalra M, Krishna D, Kursunel MA, Maurer D, Mayer-Mokler A, Mendrzyk R, Mohamed A, Pozo K, Satelli A, Letizia M, Schuster H, Schoor O, Wagner C, Rammensee HG, Reinhardt C, Singh-Jasuja H, Walter S, Weinschenk T, Luke JJ, Britten CM. Wermke M, et al. Nat Med. 2025 Jul;31(7):2365-2374. doi: 10.1038/s41591-025-03650-6. Epub 2025 Apr 9. Nat Med. 2025. PMID: 40205198 Free PMC article. Clinical Trial.